Impact of Targeted Cancer Therapy on Thinking and Memory
Official title: Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11381063 · Data updated 2026-11-12
This research looks at how targeted cancer drugs (TKIs) affect thinking and memory in patients starting treatment for certain blood cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,988,242 |
| NIH project number | 4R01CA287666-03 |
| Project ID | NIH-11381063 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with CML or CLL who are about to start TKI therapy.
✕Less likely to help
Patients not starting TKIs or with non-CML/CLL cancers may not benefit from these findings.
What this research studies
The study focuses on people with chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) who are about to begin TKI therapy. It will track cognitive changes over time using a mix of standard neuropsychological tests and real-time online assessments to capture daily cognitive fluctuations. By combining subjective reports with objective measures, the team aims to identify who is most at risk and what factors might influence CRCI during TKI treatment.
Why it matters
Potential benefit: If successful, the findings could help doctors monitor and manage cognitive side effects for patients on TKIs, improving quality of life and daily functioning.
How similar studies have gone: Prior studies have shown CRCI in cancer patients, but this is a large-scale prospective look at TKIs in hematologic cancers with new EMA-based symptom tracking.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Gonzalez, Brian D — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Gonzalez, Brian D
Related research
Other NIH-funded projects on the same topics.
-
How targeted cancer drugs affect thinking and memory
We will follow people with CML or CLL who are starting tyrosine kinase inhibitor treatment to find out if these targeted drugs change thinking, memory, or attention.
-
Effects of targeted cancer therapy on cognitive function in survivors
This study is looking at how certain cancer treatments called tyrosine kinase inhibitors (TKIs) might affect thinking and memory in people who have survived chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL), so we can better understand the challenges they face while on these therapies.
-
Improving Neurological Health with Brain Training for Mild Cognitive Impairment (INHANCE-MCI)
A computer-based brain training program is being tested to help people with mild cognitive impairment maintain thinking skills and daily functioning.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Global picture of dementia risk and memory loss across the world
A large international effort gathers data from many studies to understand how dementia and memory problems develop around the world, using shared information to reveal patterns and risk factors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.